Trial Profile

Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients, a Randomized Phase II/III Study, Double-blind and Placebo-controlled

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 06 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Potravitug (Primary)
Indications Polyomavirus infections
Focus Proof of concept; Registrational; Therapeutic Use
Acronyms SAFE KIDNEY II
Sponsors Memo Therapeutics

Most Recent Events

01 Jul 2026 Results presented in the Ipsen media release.
18 Jun 2026 According to Memo Therapeutics media release, data from this study will be presented at the American Transplant Congress (ATC) 2026, taking place from 20-24 June in Boston, USA
05 Jun 2026 According to a Memo Therapeutics media release, the additional data analysis from the study were presented at the European Renal Association (ERA) Congress 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com